[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 8, Number 4 (7-2017) ::
Caspian J Intern Med 2017, 8(4): 228-238 Back to browse issues page
Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside
Ehsan Saburi, Amin Saburi, Mostafa Ghanei *
MD Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran , mghaneister@gmail.com
Abstract:   (375 Views)

Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics medications can also enhance immune-cell activity against tumors. Such medications show great potential in cancer immunotherapy using natural human mechanisms against neoplasms.

Keywords: Cancer, Immunotherapy, Macrophage activating factor, GC-MAF, Vitamin D.
Full-Text [PDF 548 kb]   (31 Downloads)    
Type of Study: Review Article | Subject: Oncology
Received: 2016/08/22 | Accepted: 2017/03/6 | Published: 2017/07/29
Send email to the article author

Add your comments about this article
Your username or email:

Write the security code in the box >



DOI: 10.22088/cjim.8.4.228


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Saburi E, Saburi A, Ghanei M. Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside . Caspian J Intern Med. 2017; 8 (4) :228-238
URL: http://caspjim.com/article-1-847-en.html
Volume 8, Number 4 (7-2017) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.048 seconds with 791 queries by yektaweb 3461